Cloning of variable fragments of tumor immunoglobulin, assembling and expressing of human SCFV protein in E. coli for anti-idiotype vaccination

Experimental Oncology

Volumn 35, Issue 1, 2013, Pages

  Meleshko, A N ^a   Vashkevich, K P ^a   Fomina, E G ^b   Scheslenok, E P ^b   Schkolina, T V ^b   Sergeev, G V ^c  

^a Belarusian Research Center for Pediatric Oncology and Hematology   (Belarus)

^b Republican Research and Practical Center for Epidemiology and Microbiology   (Belarus)

^c INSTITUTE OF BIOORGANIC CHEMISTRY   (Belarus)

Author keywords

Idiotype; Immunoglobulin; Lymphoma; Vaccine

Indexed keywords

IMMUNOGLOBULIN IDIOTYPE; METAL CHELATE; RECOMBINANT PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; CANCER ANTIBODY; CANCER VACCINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOGLOBULIN M;

ARTICLE; CASE REPORT; CHROMATOGRAPHY; CONTROLLED STUDY; ENTAMOEBA COLI; GENE EXPRESSION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; IMMUNOGLOBULIN GENE; IMMUNOGLOBULIN VARIABLE REGION; LYMPHOMA CELL; MOLECULAR CLONING; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; VACCINATION; B CELL LYMPHOMA; B LYMPHOCYTE; ESCHERICHIA COLI; GENE AMPLIFICATION; GENETICS; IMMUNOLOGY; NUCLEOTIDE SEQUENCE; TUMOR CELL LINE;

ANTIBODIES, NEOPLASM; B-LYMPHOCYTES; BASE SEQUENCE; CANCER VACCINES; CELL LINE, TUMOR; CLONING, MOLECULAR; ESCHERICHIA COLI; GENE AMPLIFICATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN IDIOTYPES; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOGLOBULIN M; LYMPHOMA, B-CELL; SINGLE-CHAIN ANTIBODIES;

EID: 84879594690     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Kwak LW, Campbell MJ, Czerwinski DK, et al. Induction of immune responses in patients with Bcell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992; 327: 1209-15.
2. Timmerman JM, Czerwinski DK, Davis TA, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002; 99: 1517-26. (Pubitemid 34533020)
3. Inoges S, Rodriguez-Calvillo M, Zabalegui N, et al. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst 2006; 98: 1292-301. (Pubitemid 44530725)
4. Ruffini PA, Neelapu SS, Kwak LW, et al. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. Haematologica 2002; 87: 989-1001.
5. Kretzschmar T, Aoustin L, Zingel O, et al. High-level expression in insect cells and purification of secreted monomeric single-chain Fv antibodies. Immunol Methods 1996; 195: 93-101. (Pubitemid 26292692)
6. McCormick AA, Kumagai MH, Hanley K, et al. Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants. Proc Natl Acad Sci U S A 1999; 96: 703-8. (Pubitemid 29061272)
7. McCormick AA, Reinl SJ, Cameron TI, et al. Individualized human scFv vaccines produced in plants: humoral anti-idiotype responses in vaccinated mice confirm relevance to the tumor Ig. J Immunol Methods 2003; 278: 95-104. (Pubitemid 37287600)
8. McCormick AA, Reddy S, Reinl SJ, et al. Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study. Proc Natl Acad Sci U S A 2008; 105: 10131-6.
9. Bertinetti C, Simon F, Zirlik K, et al. Cloning of idiotype immunoglobulin genes in B cell lymphomas by anchored PCR and production of individual recombinant idiotype vaccines in Escherichia coli. Eur J Haematol 2006; 77: 395-402. (Pubitemid 44483942)
10. Patel KG, Ng PP, Levy S, et al. Escherichia coli-based production of a tumor idiotype antibody fragment - tetanus toxin fragment C fusion protein vaccine for B cell lymphoma. Protein Expr Purif 2011; 75: 15-20.
11. Kanter G, Yang J, Voloshin A, et al. Cell-free production of scFv fusion proteins: an efficient approach for personalized lymphoma vaccines. Blood 2007; 109: 3393-9. (Pubitemid 46572528)
12. Yang J, Kanter G, Voloshin A, et al. Rapid expression of vaccine proteins for B-cell lymphoma in a cell-free system. Biotechnol Bioeng 2005; 89: 503-11. (Pubitemid 40444804)
13. Bendandi M, Gocke CD, Kobrin CB, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999; 5: 1171-7. (Pubitemid 29474422)
14. Osterroth F, Garbe A, Fisch P, et al. Stimulation of cytotoxic T cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells. Blood 2000; 95: 1342-9. (Pubitemid 30099845)
15. Spellerberg MB, Zhu D, Thompsett A, et al. DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C. J Immunol 1997; 159: 1885-92. (Pubitemid 127484177)
16. Rinaldi M, Ria F, Parrella P, et al. Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells. Cancer Res 2001; 61: 1555-62. (Pubitemid 34292587)
17. Stevenson FK, Rice J, Ottensmeier CH, et al. DNA fusion gene vaccines against cancer: from the laboratory to the clinic. Immunol Rev 2004; 199: 156-80. (Pubitemid 38736770)
18. Sahota SS, Townsend M, Stevenson FK. Identification and assembly of V genes as idiotype-specific DNA fusion vaccines in multiple myeloma. Methods Mol Med 2005; 113: 105-19.
19. Osterroth F, Alkan O, Mackensen A, et al. Rapid expression cloning of human immunoglobulin Fab fragments for the analysis of antigen specificity of B cell lymphomas and anti-idiotype lymphoma vaccination. J Immunol Methods 1999; 229: 141-53. (Pubitemid 29505190)
20. Lu M, Gong XG, Yu H, et al. Cloning, expression, purification, and characterization of LC-1 ScFv with GFP tag. J Zhejiang Univ Sci B 2005; 6: 832-7. (Pubitemid 41319099)
21. Sakamoto S, Taura F, Putalun W, et al. Construction and expression of specificity-improved single-chain variable fragments against the bioactive naphthoquinone, plumbagin. Biol Pharm Bull 2009; 32: 434-9.
22. Schmitt J, Hess H, Stunnenberg HG. Affinity purification of histidine-tagged proteins. Mol Biol Rep 1993; 18: 223-30. (Pubitemid 2006346)
23. Schuurman HJ, van Baarlen J, Huppes W, et al. Immunophenotyping of non-Hodgkin's lymphoma. Lack of correlation between immunophenotype and cell morphology. Am J Pathol 1987; 129: 140-51. (Pubitemid 17157779)
24. Meleshko AN, Lipay NV, Stasevich IV, et al. Rearrangements of IgH, TCRD and TCRG genes as clonality marker of childhood acute lymphoblastic leukemia. Exp Oncol 2005; 27: 319-24. (Pubitemid 43139365)
25. Savelyeva N, Munday R, Spellerberg MB, et al. Plant viral genes in DNA idiotypic vaccines activate linked CD4+ T-cell mediated immunity against B-cell malignancies. Nat Biotechnol 2001; 19: 760-4. (Pubitemid 32729539)
26. Redfern CH, Guthrie TH, Bessudo A, et al. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. J Clin Oncol 2006; 24: 3107-12. (Pubitemid 46638948)
27. Schuster SJ, Neelapu SS, Gause BL, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol 2011; 29: 2787-94.
28. Bendandi M. Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures. Nat Rev Cancer 2009; 9: 675-81.
29. Inogés S, de Cerio AL, Villanueva H, et al. Idiotype vaccines for lymphoma therapy. Expert Rev Vaccines 2011; 10: 801-9.
30. Mahaseth H, Brody JD, Sinha R, et al. Idiotype vaccine strategies for treatment of follicular lymphoma. Future Oncol 2011; 7: 111-22.
31. Bendandi M, Marillonnet S, Kandzia R, et al. Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin's lymphoma. Ann Oncol 2010; 21: 2420-7.
32. Lu Z, Masaki T, Shoyama Y, et al. Construction and expression of a single chain Fv fragment against pharmacologically active paeoniflorin in Escherichia coli, and its potential use in an enzyme-linked immunosorbent assay. Planta Med 2006; 72: 151-5.
33. Pacheco B, Crombet L, Loppnau P, et al. A screening strategy for heterologous protein expression in Escherichia coli with the highest return of investment. Protein Expr Purif 2012; 81: 33-41
34. Gnoth S, Simutis R, Lübbert A. Selective expression of the soluble product fraction in Escherichia coli cultures employed in recombinant protein production processes. Appl Microbiol Biotechnol 2010; 87: 2047-58. Sciences